Home > > > > Report Detail

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018

Publisher Name :
Date: 01-Mar-2018
No. of pages: 344
Inquire Before Buying

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies.

This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report covers details of co-promotion and co-marketing agreements from 2012 to 2018.

For pharmaceutical and biotechnology professionals, the report supplies a detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals. The majority of deals are multicomponent whereby the licensor retains either a right or option to co-promote/market the resultant product of the research collaboration. There are also numerous pure co-promotion/marketing deals whereby the products originator takes on a co-promotion/marketing partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all co-promotion and co-marketing deals announced since 2012 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-promotion and co-marketing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of co-promotion and co-marketing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in co-promotion and co-marketing as well as a discussion on the merits of each type of deal.

Chapters 3 and 4 provide an overview of the structure of co-promotion and co-marketing deals, respectively. Each chapter includes numerous case studies to enable understanding of both pure co-promotion/marketing deals and multicomponent deals where co-promotion/marketing forms a part.

Chapter 5 provides a review of the leading co-promotion and co-marketing deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 6 provides a review of the top 50 most active biopharma companies in co-promotion and co-marketing. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 7 provides a comprehensive and detailed review of co-promotion and co-marketing deals signed and announced since 2012 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous table and figures that illustrate the trends and activities in co-promotion and co-marketing deal making since 2012.

In addition, a comprehensive appendix is provided organized by co-promotion and co-marketing company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-promotion and co-marketing partnering in the research, development and commercialization of technologies and products.

Key benefits

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides the reader with the following key benefits:

In-depth understanding of co-promotion and co-marketing deal trends since 2012

Analysis of the structure of co-promotion and co-marketing agreements with numerous real life case studies

Comprehensive access to over 700 actual co-promotion and co-marketing deals entered into by the world's biopharma companies

Insight into the terms included in a co-promotion and co-marketing agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report is intended to provide the reader with an in-depth understanding of the co-promotion and co-marketing trends and structure of deals entered into by leading biopharma companies worldwide.

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 includes:

Trends in co-promotion and co-marketing dealmaking in the biopharma industry since 2012

Analysis of co-promotion and co-marketing deal structure

Case studies of real-life co-promotion and co-marketing deals

Access to over 700 co-promotion and co-marketing deal records

Detailed access to actual co-promotion contract documents

The leading co-promotion and co-marketing deals by value since 2012

Most active co-promotion and co-marketing dealmakers since 2012

The leading co-promotion and co-marketing partnering resources

In Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Therapeutic area

Technology area

Each deal title links via Weblink to an online version of deal record as found in the Current Agreements deals and alliances database, providing easy access to each deal record on demand.

The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive access to records for over 700 co-promotion and co-marketing deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise co-promotion and co-marketing rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresalesand payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-promotion and co-marketing dealmaking
2.1. Introduction
2.2. Difference between co-promotion and co-marketing deals
2.3. Trends in co-promotion deals since 2012
2.3.1. Co-promotion and co-marketing dealmaking by year, 2012 to 2018
2.3.2. Co-promotion and co-marketing dealmaking by phase of development, 2012 to 2018
2.3.3. Co-promotion and co-marketing dealmaking by industry sector, 2012 to 2018
2.3.4. Co-promotion and co-marketing dealmaking by therapy area, 2012 to 2018
2.3.5. Co-promotion and co-marketing dealmaking by technology type, 2012 to 2018
2.3.6. Co-promotion and co-marketing dealmaking by most active company, 2012 to 2018
2.4. When co-marketing can be useful
2.5. When co-marketing is the only option
2.6. Pure deals and multi-component deals
2.6.1. Attributes of pure co-promotion deals
2.6.2. Attributes of co-promotion in multi-component deals
2.7. Reasons for including co-promotion options in a deal
2.8. Uptake of co-promotion rights
2.9. Co-promotion rights as bargaining chips
2.10. Aligning partners to make the co-promote work
2.11. The future of co-promotion as part of multicomponent deals

Chapter 3 - Overview of co-promotion deal structure
3.1. Introduction
3.2. Pure versus multi-component co-promotion deals
3.3. Pure co-promotion agreement structure
3.3.1. Example co-promotion agreements
3.3.1.a. Case study 1: Allergan - MAP Pharmaceuticals
3.3.1.b. Case study 2: Genzyme - Veracyte
3.4. Co-promotion rights as part of a wider alliance agreement
3.4.1. Example co-promotion option clauses
3.4.1.a. Case study 3: Takeda Pharmaceutical- Orexigen Therapeutics
3.4.1.b. Case study 4: Celgene - Acceleron Pharma
3.4.2. Example co-promotion right clauses
3.4.2.a. Case study 5: Takeda - Orexigen
3.4.2.b. Case study 6: Abbvie - Receptos
3.5. Embedded co-promotion rights enabling third party engagement
3.5.1. Example co-promotion clauses enabling third party engagement
3.5.1.a. Case study 7: Astellas - Ambit Biosciences

Chapter 4 - Overview of co-marketing deal structure
4.1. Introduction
4.2. Co-marketing agreement structure
4.2.1. Example co-marketing agreements
4.2.1.a. Case study 8: AstraZeneca -Ironwood Pharmaceuticals
4.3. Co-marketing rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 9: Lundbeck - Myriad Genetics

Chapter 5 - Leading co-promotion and co-marketing deals
5.1. Introduction
5.2. Top co-promotion and co-marketing deals by value

Chapter 6 - Top 50 most active co-promotion and co-marketing dealmakers
6.1. Introduction
6.2. Top 50 most active co-promotion and co-marketing dealmakers

Chapter 7 - Co-promotion and co-marketing agreement contracts directory 2012- 2018
7.1. Introduction
7.2. Co-promotion and co-marketing deals with contracts 2012 to 2018

Appendices
Appendix 1 - Co-promotion and co-marketing deals by company A-Z
Appendix 2 - Co-promotion and co-marketing deals by stage of development
Appendix 3 - Co-promotion and co-marketing deals by deal type
Appendix 4 - Co-promotion and co-marketing deals by therapy area
Appendix 5 - Co-promotion and co-marketing deals by technology type
Appendix 6 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Definition of co-promotion and co-marketing
Figure 2: Trends in co-promotion and co-marketing deal announcements, 2012 to 2018
Figure 3: Co-promotion and co-marketing deals signed at each phase of development, 2012 to 2018
Figure 4: Co-promotion and co-marketing deals by industry sector, 2012 to 2018
Figure 5: Co-promotion and co-marketing deals by therapy area, 2012 to 2018
Figure 6: Co-promotion and co-marketing deals by technology type, 2012 to 2018
Figure 7: Top 50 most active co-promotion and co-marketing dealmakers, 2012 to 2018
Figure 8: Situations where co-marketing can prove useful
Figure 9: Key components of a pure co-promotion deal
Figure 10: Key components of a multi-component co-promotion deal
Figure 11: Example deals where co-promotion options have been actively exercised, since 2000
Figure 12: Issues in implementing co-promotion agreements
Figure 13: Co-promotion agreements - what should a contract include?
Figure 14: Components of the co-promotion deal structure
Figure 15: Components of the co-marketing deal structure
Figure 16: Top co-promotion and co-marketing deals by value since 2012
Figure 17: Most active co-promotion and co-marketing dealmakers 2012 to 2018
  • Worldwide Pharmaceutical Mergers And Acquisitions Market Research Report 2021 by Type, Application, Participants and Countries, COVID-19 Impact, Forecast Year to 2026
    Published: 29-Apr-2021        Price: US 3340 Onwards        Pages: 119
    Due to the high popularity of this product/service in North America and Asia, the growth trend of Pharmaceutical Mergers And Acquisitions in recent years and the growth of consumers' demand is expected to drive the global Pharmaceutical Mergers And Acquisitions market. Geographically, the global Pharmaceutical Mergers And Acquisitions market is divided into North America, Europe, Latin America, Asia Pacific, Middle East & Africa. North America, Asia and Europe have significant......
  • Pharmerging Contract Manufacturings Market Insights 2020, Global and Chinese Analysis and Forecast to 2025
    Published: 10-Dec-2020        Price: US 3000 Onwards        Pages: 135
    Pharmerging Contract Manufacturings Market Insights 2020, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmerging Contract Manufacturings industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmerging Contract Manufacturings manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.Overall, the report provides an in-depth......
  • Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Analysis and Forecast to 2024
    Published: 21-Mar-2020        Price: US 3000 Onwards        Pages: 149
    Pharmerging Contract Manufacturings Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Pharmerging Contract Manufacturings industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pharmerging Contract Manufacturings manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-dept......
  • Mergers and Acquisitions in Chinese Pesticide Industry in 2018-2019
    Published: 06-Jan-2020        Price: US 1080 Onwards        Pages: 19
    In recent years, establishing large business groups by mergers and acquisitions (M&As) to expand production scale of enterprises has been one main guideline of the Chinese government for the pesticide industry. M&As has also become one of the key words in Chinese pesticide industry. As the deadline of China's 13th Five-year Plan period (2016-2020) is coming, it's likely that China will see more M&A activities. M&A is companies' normal response when they suffered market depression.......
  • Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 344
    The Global Co-promotion and Co-marketing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the ......
  • Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 348
    The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered i......
  • Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018
    Published: 01-Oct-2018        Price: US 1995 Onwards        Pages: 350
    The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing partnering agreements entered into by the worlds leading healthcare companies. The Global Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2018 report provides comprehensive understanding and unprecedented access to the royalty financing agreem......
  • Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012 to 2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 457
    The Global Co-development Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies. The Global Co-development Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered ......
  • Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech & Diagnostics 2012-2018
    Published: 01-Oct-2018        Price: US 2995 Onwards        Pages: 2000
    The Global Collaborative R&D Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D partnering deals and agreements entered into by the worlds leading healthcare companies. The Global Collaborative R&D Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides comprehensive understanding and unprecedented access to the collaborative R&D deals an......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs